Skip to main content
Johnson & Johnson
SciBX: Science-Business eXchange
As published Thursday, May 23, 2013


  • Cover Story: IRS audit for tumors

    By Lev Osherovich, Senior Writer

    An Israeli academic-industry partnership has discovered small molecules that interfere wi th signaling by insulin-like growth factor-1 receptor, a cancer-associated receptor tyrosine kinase. The new compounds, licensed to NovoTyr Therapeutics Ltd., could be superior to conventional approaches to hitting this target because they cause destruction of two key downstream effectors, insulin receptor substrate 1 and insulin receptor substrate 2.1

    Excessive activity of insulin-like growth factor-1 receptor (IGF1R; CD221) is a common feature in many tumor types. When activated by extracellular ligands such as insulin and insulin-like growth factor-1 (IGF-1), IGF1R recruits the intracellular proteins insulin receptor substrate 1 (IRS1) and IRS2 to relay a proliferative signal to a range of downstream pathways that drive tumor growth.2

    Full Article
  • Revisiting adrenomedullin in pre-eclampsia

    A North Carolina team has shown that fetal deficiency in adrenomedullin resulted in mouse placental abnormalities similar to those found in pre-eclampsia. The results point to adrenomedullin as a potential marker for the indication.

  • Finding a home for nuclear transfer

    Oregon Health & Science University researchers have for the first time generated stable lines of human embryonic stem cells via somatic cell nuclear transfer. Whether the platform can carve a niche among existing stem cell-based techniques will hinge on how the cells compare with those generated through other approaches.

  • Oxford goes big (data)

    University of Oxford is bringing big data to translational research. The university, the U.K. government and a philanthropist are infusing up to L90 million ($138.3 million) to set up a new hub that will use large-scale data analysis to improve the odds of identifying clinically relevant molecular targets.

Distillery

  • This Week in Therapeutics

    Treating aromatase inhibitor-resistant breast cancer with RET inhibitors; enhancing the efficacy of antidepressant drugs with RGS4 modulators; treating Cushing's disease with TR4 inhibitors; and more...

  • more therapeutics news
  • This Week in Techniques

    Postsurgical resection model for metastatic breast cancer; collagen-like, cell-penetrating peptides for drug delivery; classification system for endometrial cancers; and more...

  • more techniques news
Subscribe Now
Free Trial
Keck Graduate Institute

SciBX: Science-Business eXchange

BioCentury's weekly translational science journal, published in collaboration with Nature Publishing Group:

  • Selects from hundreds of scientific papers published each week to identify early opportunities for investment, alliances and partnerships
  • Reports on the most commercially relevant developments

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

Get  Free Trial